Metabolic syndrome is a cluster of interrelated cardiometabolic risk factors that significantly increase the risk for Type 2 diabetes, cardiovascular disease, and stroke. Diagnostic criteria (as defined by the International Diabetes Federation and other organizations) include central obesity, elevated triglycerides, reduced HDL cholesterol, hypertension, and impaired fasting glucose. The syndrome reflects a shared pathophysiology driven largely by insulin resistance, visceral adiposity, chronic inflammation, and hormonal imbalances. It is highly prevalent globally, particularly in populations with sedentary lifestyles, poor dietary habits, and genetic predisposition. Individuals with metabolic syndrome are at a twofold increased risk of cardiovascular events and a fivefold increased risk of developing Type 2 diabetes. Management focuses on aggressive lifestyle modification—dietary changes, physical activity, weight reduction—as well as targeted pharmacotherapy to address dyslipidemia, hypertension, and hyperglycemia. Early identification and intervention are essential to prevent progression to overt disease. Moreover, public health strategies that promote healthy environments and address socioeconomic factors are key to reducing the global burden of metabolic syndrome.